Business, energy, technology, markets and global industry news from Business News Today

immune checkpoint inhibitors

PharmaDeviceNews immune checkpoint inhibitors
Representative image: Clinical analytics and gastrointestinal imaging scene reflecting Seres Therapeutics’ SER-155 data in checkpoint inhibitor-related enterocolitis and the emerging role of microbiome therapeutics in cancer supportive care.
Pharma & Biotech

Why SER-155 could become a key clinical catalyst for Seres Therapeutics

Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at

Read More
Representative image: Samsung Bioepis’ SB27 Keytruda biosimilar trial results highlight a potentially important step toward lower-cost pembrolizumab competition in the global oncology market.
Pharma & Biotech

Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates

Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.

Read More
Pharma & Biotech

Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies

Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.

Read More
Pharma & Biotech

Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?

Kazia Therapeutics Limited has presented new clinical and translational data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its investigational brain-penetrant PI3K/mTOR inhibitor, may suppress circulating tumor cell clusters and reverse immune exhaustion in two of the most treatment-resistant breast cancer subtypes—HER2-positive metastatic breast cancer and triple-negative breast cancer. The early evidence,

Read More